Related Experiment Video
Updated: Jul 16, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
The idiopathic inflammatory myopathies module of the Rheumatic Diseases Portuguese Register
Eduardo Dourado1, Ana Teresa Melo1, Raquel Campanilho-Marques1
1Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa.
Aims:
To characterise the idiopathic inflammatory myopathies (IIM) module of the Rheumatic Diseases Portuguese Register (Reuma.pt/myositis) and the patients in its cohort.
Methods:
Reuma.pt is a web-based system with standardised patient files gathered in a registry. This was a multicentre open cohort study, including patients registered in Reuma.pt/myositis up to January 2022.
Results:
Reuma.pt/myositis was designed to record all relevant data in clinical practice and includes disease-specific diagnosis and classification criteria, clinical manifestations, immunological data, and disease activity scores. Two hundred eighty patients were included, 71.4% female, 89.4% Caucasian, with a median age at diagnosis and disease duration of 48.9 (33.6-59.3) and 5.3 (3.0-9.8) years. Patients were classified as having definite (N=57/118, 48.3%), likely (N=23/118, 19.5%), or possible (N=2/118, 1.7%) IIM by 2017 EULAR/ACR criteria. The most common disease subtypes were dermatomyositis (DM, N=122/280, 43.6%), polymyositis (N=59/280, 21.1%), and myositis in overlap syndromes (N=41/280, 14.6%). The most common symptoms were proximal muscle weakness (N=180/215, 83.7%) and arthralgia (N=127/249, 52.9%), and the most common clinical signs were Gottron's sign (N=75/184, 40.8%) and heliotrope rash (N=101/252, 40.1%). Organ involvement included lung (N=78/230, 33.9%) and heart (N=11/229, 4.8%) involvements. Most patients expressed myositis-specific (MSA, N=158/242, 65.3%) or myositis-associated (MAA, 112/242, 46.3%) antibodies. The most frequent were anti-SSA/SSB (N=70/231, 30.3%), anti-Jo1 (N=56/236, 23.7%), and anti-Mi2 (N=31/212, 14.6%). Most patients had a myopathic pattern on electromyogram (N=101/138, 73.2%), muscle oedema in magnetic resonance (N=33/62, 53.2%), and high CK (N=154/200, 55.0%) and aldolase levels (N=74/135, 54.8%). Cancer was found in 11/127 patients (8.7%), most commonly breast cancer (N=3/11, 27.3%). Most patients with cancer-associated myositis had DM (N=8/11, 72.7%) and expressed MSA (N=6/11) and/or MAA (N=3/11). The most used drugs were glucocorticoids (N=201/280, 71.8%), methotrexate (N=117/280, 41.8%), hydroxychloroquine (N=87/280, 31.1%), azathioprine (N=85/280, 30.4%), and mycophenolate mofetil (N=56/280, 20.0%). At the last follow-up, there was a median MMT8 of 150 (142-150), modified DAS skin of 0 (0-1), global VAS of 10 (0-50) mm, and HAQ of 0.125 (0.000-1.125).
Conclusions:
Reuma.pt/myositis adequately captures the main features of inflammatory myopathies' patients, depicting, in this first report, a heterogeneous population with frequent muscle, joint, skin, and lung involvements.
Insights
The Reuma.pt/myositis registry effectively characterizes idiopathic inflammatory myopathies (IIM) patients, revealing a diverse cohort with common muscle, joint, skin, and lung involvement. This study highlights the registry's utility in understanding IIM patient populations.
Area of Science:
- Rheumatology
- Clinical Research
- Patient Registries
Background:
- Idiopathic inflammatory myopathies (IIM) represent a group of rare autoimmune diseases affecting muscles.
- Understanding the characteristics and clinical course of IIM patients is crucial for effective management.
- The Rheumatic Diseases Portuguese Register (Reuma.pt) established a specific module (Reuma.pt/myositis) to capture comprehensive data on IIM.
Purpose of the Study:
- To characterize the idiopathic inflammatory myopathies (IIM) module within the Reuma.pt registry.
- To describe the demographic, clinical, immunological, and treatment features of patients in the Reuma.pt/myositis cohort.
Main Methods:
- A multicentre open cohort study utilizing the Reuma.pt/myositis web-based registry.
- Inclusion of patients registered up to January 2022, with data on diagnosis, clinical manifestations, immunological markers, and disease activity.
- Analysis of 280 patients classified according to 2017 EULAR/ACR criteria.
Main Results:
- The cohort comprised 71.4% females, predominantly Caucasian, with a median age at diagnosis of 48.9 years.
- Dermatomyositis (43.6%) was the most common subtype, followed by polymyositis (21.1%).
- Frequent manifestations included proximal muscle weakness (83.7%), lung involvement (33.9%), and presence of myositis-specific antibodies (65.3%).
- Glucocorticoids (71.8%) and methotrexate (41.8%) were the most common treatments.
Conclusions:
- The Reuma.pt/myositis registry successfully captures key characteristics of IIM patients.
- The study depicts a heterogeneous IIM population with significant involvement of muscles, joints, skin, and lungs.
- This initial report underscores the value of the registry for epidemiological and clinical research in IIM.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease IV: Nursing Management

